REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs Yokohama, Japan / Long Island City, NY – [September 28th,2026] — REPROCELL (Yokohama, Japan; TYO: 4978) and Polyphron, Inc. (Long Island City, NY) are pleased to announce their collaboration under which REPROCELL will supply its proprietary StemRNA™ iPSCs for use across…
Yokohama, Japan / Suzhou, China – July 27, 2026 – REPROCELL Inc., a global provider of clinical-grade iPSC technologies and regenerative medicine solutions, today announced a strategic collaboration with WEIPU Biotechnology Co., Ltd., a biotechnology company based in Suzhou, China, to support cell therapy developers in China with access to high-quality clinical starting materials and…
JAPAN, June 24, 2026 – REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with…
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…
January 28th, 2026 – REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL’s StemRNA™ Clinical…
Yokohama, Japan / Bilbao, Spain – October 20th — REPROCELL (Yokohama, Japan; TYO: 4978) and Histocell (Bilbao, Spain) are proud to announce that the Spanish Agency for Medicines and Medical Devices (AEMPS), operating under European Medicines Agency (EMA) oversight, has granted to Histocell Good Manufacturing Practice (GMP) certificate and authorization of the manufacturing process of induced Pluripotent…
Yokohama, Japan, August 20, 2025 REPROCELL is proud to announce the introduction of NeoSight – Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications. This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal…
Glasgow, UK — Scientists from REPROCELL Europe, working in collaboration with researchers at Durham University, have successfully developed a full-thickness human skin model using fibroblasts derived from induced pluripotent stem cells (iPSCs). The breakthrough, published in Cells (14(14):1044, 2025), demonstrates a novel approach to producing consistent, high-quality human skin constructs for research and therapeutic applications. Current skin models…
Hyderabad, India: Bioserve Biotechnologies India Pvt. Ltd. has entered into an exclusive distribution agreement with HLB PEP Co., Ltd. (Republic of Korea) for the Indian market. Under this agreement, Bioserve will begin distributing peptides manufactured by HLB PEP. Bioserve is a leading provider of DNA synthesis and genetic analysis services in India. Since its establishment, the…
YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…